Banner image is AI generated

Purpose

To determine whether an Early Highly Effective Treatment (EHT) approach to Disease Modifying Therapy (DMT) as first-line therapy, is more effective than an escalation of treatment approach in reducing normalized whole brain volume loss measured using MRI in PwRRMS from Baseline to Month 36.

Patient Population

Adult men and women aged 18-60 years, inclusive, with established diagnosis of MS, as defined by the 2017 revision of McDonald Diagnostic Criteria, with RRMS.

Participants must have evidence of active disease, and enrolled participants must be ambulatory with disease onset within 5 years, treatment naïve, and eligible to receive at least one DMT in each arm. 

Research Method

DELIVER-MS is a multi-center, pragmatic, comparative effectiveness, randomized, clinical trial with additional-parallel observational cohort.